CATB on NASDAQ

Catabasis Pharmaceuticals

We are a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases.4 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

2008Founded1

Compare with DiaMedica Therapeutics Inc., EXICURE, INC. or Imunon, Inc., or pick any stock.

  • TickerCATB on NASDAQ1
  • IndustryPharmaceutical Preparations1
  • HeadquartersCambridge1
  • Websitewww.catabasis.com
  • Incorporated inDE3
  • Business address22 Boston Wharf Road, 10Th Floor, Boston, Ma 022103
  • Filer categoryNon-accelerated filer, Smaller reporting company3

See how the biggest companies compare on our leaderboards

We are a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for allergic and immunological diseases. Our focus is to develop first-choice therapies that improve the health and outcomes of patients with allergic and immunologic diseases. Our lead product candidate is navenibart, formerly known as STAR-0215, a potential best-in-class monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema, or HAE, a rare, debilitating and potentially life-threatening disease. We believe that navenibart has the potential to be the market - leading and most patient-friendly chronic treatment option for HAE, based on proof-of-concept data in HAE patients and the existing HAE treatment landscape. Our second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in clinic…4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2020

-91.7%Return on equity5
-$32.5MFree cash flow6

Financial statements

Revenue78$0 in 2020
02018: $0$020182020: $0$02020
Operating income986-$37.4M in 2020+42% since 2018
-$40.0M-$30.0M-$20.0M-$10.0M02018: -$26.4M-$26.4M20182019: -$27.1M-$27.1M2019+3%2020: -$37.4M-$37.4M2020+38%
Net income986-$37.3M in 2020+44% since 2018
-$40.0M-$30.0M-$20.0M-$10.0M02018: -$25.9M-$25.9M20182019: -$26.3M-$26.3M2019+2%2020: -$37.3M-$37.3M2020+42%
Fiscal year201820192020
Revenue$07$08
Research and development$17.0M9$18.3M8$25.6M8
Operating expenses
Operating income-$26.4M9-$27.1M8-$37.4M6
Interest$100.0K7
Net income-$25.9M9-$26.3M8-$37.3M6
Earnings per share-$12.206
Earnings per share (diluted)-$12.206
Shares (weighted, basic)
Shares (weighted, diluted)

Compare Catabasis Pharmaceuticals with another company

Leadership

Who has led Catabasis Pharmaceuticals, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Jill C. Milne2015–now

President

  1. Jill C. Milne2015–now

Chief financial officer

  1. Ian C. Sanderson2015–2016
  2. Noah Clauser2020–now
2010201520202025
Board members and other officers (25)

Former names

  • CATABASIS PHARMACEUTICALS INCJan 21, 2009 to Aug 20, 20213

Timeline

  1. Jun 24, 2015New chief executive Jill C. Milne becomes CEO12
  2. 2008Founded Founded1

Filings

276 filings to the SEC since October 2021: 4 annual reports, 13 quarterly reports, 36 major events, 87 insider forms, 64 large holders, 72 other. The latest 20:

  1. Feb 17, 2026SCHEDULE 13G/A EDGAR
  2. Feb 12, 2026SCHEDULE 13G/A EDGAR
  3. Feb 9, 2026SCHEDULE 13D/A EDGAR
  4. Feb 2, 202615-12G EDGAR
  5. Jan 28, 2026SCHEDULE 13D/A EDGAR
  6. Jan 27, 2026EFFECT EDGAR
  7. Jan 27, 2026EFFECT EDGAR
  8. Jan 27, 2026EFFECT EDGAR
  9. Jan 27, 2026EFFECT EDGAR
  10. Jan 27, 2026EFFECT EDGAR
  11. Jan 27, 2026EFFECT EDGAR
  12. Jan 23, 2026S-8 POS EDGAR
  13. Jan 23, 2026S-8 POS EDGAR
  14. Jan 23, 2026S-8 POS EDGAR
  15. Jan 23, 2026S-8 POS EDGAR
  16. Jan 23, 2026S-8 POS EDGAR
  17. Jan 23, 2026S-8 POS EDGAR
  18. Jan 23, 2026S-8 POS EDGAR
  19. Jan 23, 2026S-8 POS EDGAR
  20. Jan 23, 2026S-8 POS EDGAR

The 276 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

8 open-market trades by officers, directors and large owners since October 2021: 5 buys and 3 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 1, 2024Morabito ChristopherChief Medical OfficerSale10,000$13.59$135.9KForm 4
Feb 1, 2024Perceptive Xontogeny Venture Fund, LPDirectorBuy2,481,350$12.09$30.0MForm 4
Jan 29, 2024Morabito ChristopherChief Medical OfficerSale9,200$11.15$102.6KForm 4
Jan 26, 2024Morabito ChristopherChief Medical OfficerSale800$11.02$8.8KForm 4
Dec 21, 2023PERCEPTIVE ADVISORS LLCDirectorBuy740,000$6.20$4.6MForm 4
Oct 16, 2023PERCEPTIVE LIFE SCIENCES MASTER FUND LTDDirectorBuy1,074,608$6.51$7.0MForm 4
Dec 19, 2022PERCEPTIVE LIFE SCIENCES MASTER FUND LTDDirectorBuy908,265$11.01$10.0MForm 4
Nov 19, 2021Komjathy AndrewChief Commercial OfficerBuy100$6.70$670Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56